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Lithium salts are used widely for treatment of bipolar and other mental disorders. Lithium
therapy is accompanied frequently by renal side effects, such as nephrogenic diabetes
insipidus or chronic kidney disease (CKD), but the molecular mechanisms underlying
these effects are still poorly understood. In the present study we examined the effect
of lithium on the activity of the osmosensitive transcriptional activator nuclear factor
of activated T cells 5 (NFAT5, also known as TonEBP), which plays a key role in renal
cellular osmoprotection and urinary concentrating ability. Interestingly, we found different
effects of lithium on NFAT5 activity, depending on medium osmolality and incubation
time. When cells were exposed to lithium for a relative short period (24 h), NFAT5
activity was significantly increased, especially under isosmotic conditions, resulting in
an enhanced expression of the NFAT5 target gene heat shock protein 70 (HSP70).
Further analysis revealed that the increase of NFAT5 activity depended primarily on an
enhanced activity of the c-terminal transactivation domain (TAD), while NFAT5 protein
abundance was largely unaffected. Enhanced activity of the TAD is probably mediated
by lithium-induced inhibitory phosphorylation of glycogen synthase kinase 3β (GSK-3β),
which is in accordance with previous studies. When cells were exposed to lithium for
a longer period (96 h), cellular NFAT5 activity and subsequently expression of HSP70
significantly decreased under hyperosmotic conditions, due to diminished NFAT5 protein
abundance, also resulting from GSK-3β inhibition. Taken together, our results provide
evidence that lithium has opposing effects on NFAT5 activity, depending on environmental
osmolality and exposure duration. The potential impacts of these observations on the
diverse effects of lithium on kidney function are discussed.
Keywords: NFAT5, lithium, nephrogenic diabetes insipidus, GSK3β, urinary concentrating mechanism, chronic
kidney disease
Introduction
The beginning of the widespread use of lithium as a mood stabilizer in the treatment of
bipolar disorders in the early 1970s also saw the first reports of adverse renal side effects
accompanying lithium treatment. The most common adverse effect is nephrogenic diabetes
insipidus (NDI), due to a decreased expression of the aquaporin-2 (AQP-2) water channel and
incorrect trafficking of AQP-2 to the luminal membrane in collecting duct cells (Marples et al.,
1995; Kwon et al., 2000). Lithium-induced NDI, affecting up to 40% of all patients, can be
detected within a few weeks after beginning lithium administration (Grünfeld and Rossier, 2009).
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Additionally, patients receiving lithium for more than 10 years
have a significantly increased risk of developing chronic kidney
disease (CKD; Bendz et al., 2010).
Lithium affects multiple molecular targets and signaling
pathways, making it difficult to characterize the exact
mechanisms by which the positive effects on the mood of
psychiatric patients or the renal side effects are induced. In the
last two decades, however, it has become increasingly evident that
inhibition of the glycogen synthase kinase 3β (GSK-3β; Klein and
Melton, 1996; Stambolic et al., 1996) plays a crucial role for the
effects of lithium both in neuronal and kidney cells. GSK-3β is
a ubiquitiously expressed serine/threonine kinase with multiple
downstream targets, often transcriptional regulators (Doble and
Woodgett, 2003). Under “normal” (non-stimulated) conditions
GSK-3β is in its active state. In most cases, phosphorylation by
active GSK-3β suppresses the activity of its downstream targets.
Under stimulated conditions, phosphorylation of a serine residue
(Ser9 in mouse, Ser21 in human) inactivates GSK-3β, thereby
activating downstream targets.
Recently, the osmosensitive transcription factor nuclear factor
of activated T-cells 5 [NFAT5, also known as tonicity enhancer
binding protein (TonEBP) or osmolality response element
binding protein (OREBP)] has been identified as GSK-3β
downstream target in renal cells (Zhou et al., 2013; Quadri and
Siragy, 2014). NFAT5 is an osmosensitive transcription factor
that serves two important functions in the renal medulla. First,
it regulates the expression of osmoprotective genes, such as heat
shock protein 70 (HSP70;Woo et al., 2002), aldose reductase (AR;
Ko et al., 2000), taurine transporter (TauT; Zhang et al., 2003),
sodium-myo-inositol transporter (SMIT; Miyakawa et al., 1999),
or betain-gaba transporter 1 (BGT-1; Miyakawa et al., 1998), all
of which are essential for cell survival under the hyperosmotic
conditions of the renal medulla. Second, NFAT5 (together with
other factors) regulates the expression of components of the
urinary concentration machinery, such as AQP-2 (Lam et al.,
2004; Hasler et al., 2006), or the urea transporter-1 (UT-
A; Nakayama et al., 2000). Accordingly, animal studies have
demonstrated that inhibition or downregulation of NFAT5 in
the kidney is associated with urinary concentration defects
(Lam et al., 2004) and severe renal damages (López-Rodríguez
et al., 2004). Generally, activation of NFAT5 in response to
hyperosmotic stress is mediated by an increase of NFAT5
protein abundance (Miyakawa et al., 1999) and by activation
of the c-terminal transactivation domain (TAD; Ferraris et al.,
2002), which in turn stimulates the transcriptional machinery.
The regulation of NFAT5 activity is a complex process, and
various kinases, in addition to GSK-3β, are reportedly involved,
among them p38 (Ko et al., 2002), AKT (Roth et al., 2010),
or phosphoinositide-3 kinase (PI-3K; Irarrazabal et al., 2006).
Under isosmotic conditions GSK-3β is active and suppresses
NFAT5 activation (the exact phosphorylation site within NFAT5
has not yet been identified). High osmolality activates AKT, PKA,
and PI-3K, which in turn inhibit GSK-3β, resulting in enhanced
activity of the c-terminal TAD of NFAT5 (Zhou et al., 2013).
The aim of the present study was to evaluate the effects of
lithium on the activity of NFAT5. We present evidence for two
opposing effects: short exposure enhances NFAT5 activity by
stimulation of the c-terminal TAD, while long exposure decreases
NFAT5 activity due to diminished protein abundance.
Methods
Materials
Antibodies were obtained as follows: anti-NFAT5 antibody
was from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
anti-actin antibody was from Sigma (Deisenhofen, Germany);
anti-phospho-GSK-3β (Ser9), anti-GSK-3β, anti-phospho-p38
(Thr180/Tyr182), and anti-p38 were purchased from Cell
Signaling (Beverly, MA, USA); anti-phospho-Akt (Ser473) and
anti-AKT were from Genscript (Piscataway, NJ, USA). GSK-
3β inhibitor VIII was obtained from Cayman Chemical (Ann
Arbor,MI, USA). Unless otherwise indicated, other reagents were
purchased from Biomol (Hamburg, Germany), Biozol (Eching,
Germany), Carl Roth (Karlsruhe, Germany), or Sigma.
Cell Culture
HEK293 or IMCD-3 cells were cultured in Dulbeccos modified
Eagles medium supplemented with 10% fetal bovine serum
(Biochrom, Berlin, Germany), 100 units/ml penicillin, and
100µg/ml streptomycin (Invitrogen, Karlsruhe, Germany) at
37◦C in a humidified atmosphere (95% air/5% CO2). Cells were
grown in 24-well plates to confluency. For experiments, medium
osmolality was increased by addition of NaCl. Lithiumwas added
to the medium as Li2SO4, in concentrations of 1–10mM; control
cells were treated with corresponding concentrations of Na2SO4.
GSK-3β inhibitor VIII, dissolved in DMSO, was used at a final
concentration of 10µM.
qRT-PCR Analysis
For determination of mRNA expression levels, total RNA
from IMCD-3 cells was recovered using TriFast Reagent
(Peqlab, Erlangen, Germany) according to the manufacturer’s
recommendations. The primers (Metabion, Martinsried,
Germany) used in these experiments were:
HSP70_fw: 5′-tga gtc cca cac tct cac ca-3′;
HSP70_rev: 5′-ctg tgg gtg aag ctg tta agg -3′;
NFAT5_fw: 5′-AAT CGC CCA AGT CCC TCT AC-3′;
NFAT5_rev: 5′-GGT GGT AAA GGA GCT GCA AG -3′;
actin_fw: 5′- CCA ACC GCG AGA AGA TGA-3′;
actin_rev: 5′- CCA GAG GCG TAC AGG GAT AG -3′.
Experiments were performed on a CFX Connect Real Time
PCR Detection System (BioRad, Hercules, CA, USA) using the
SensiMix SYBR One-Step Kit (Bioline, Luckenwalde, Germany)
according to the manufacturer’s recommendations. Relative
mRNA expression of the respective genes was calculated by the
2−11CT–method (Livak and Schmittgen, 2001), using β-actin as
housekeeping gene. Specificity of PCR product formation was
confirmed by monitoring melting point analysis and by agarose
gel electrophoresis.
Immunoblot Analysis
Aliquots of cell extracts from IMCD-3 cells (5–30µg protein)
were subjected to sodium dodecylsulphate polyacrylamide gel
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electrophoresis (SDS-PAGE) and blotted onto nitrocellulose
membranes (GE Healthcare, Pittsburgh, PA, USA). Non-specific
binding sites were blocked with 5% non-fat dry milk in
phosphate-buffered saline (PBS) containing 0.1% Tween-20
(PBS-T) at room temperature for 1 h. Samples were incubated
with primary antibodies in PBS-T containing 5% non-fat dry
milk over night at 4◦C. Subsequently, the blots were washed three
times with PBS-T for 5min each, and the membranes incubated
with appropriate secondary antibody at room temperature for
1 h in PBS-T containing 5% non-fat dry milk. After washing
with PBS-T three times for 5min each, immunocomplexes were
visualized by enhanced chemiluminescence.
Determination of NFAT5 Cellular Activity
NFAT5 transcriptional activity was assessed using the secreted
alkaline phosphatase system (SEAP) with a reporter construct
in which the SEAP open reading frame is under control of
two TonE sites. Generation of stably transfected HEK293-pSeap-
TonE cells is described elsewhere (Neuhofer et al., 2007). After
growing to confluency, the cells were treated as indicated and
SEAP activity in the medium determined as described in detail
elsewhere (Neuhofer et al., 2007). In experiments in which cells
were exposed for 96 h to the respective stimulus, medium was
changed after 72 h to ensure that SEAP activity in the medium
reflects the actual NFAT5 cellular activity.
Determination of NFAT5 Transactivating Activity
NFAT5 transactivating activity in HEK293 cells was determined
using the Gal4 binary assay as described elsewhere (Ferraris
et al., 2002; Küper et al., 2012). Gal4-TonEBP-TAD contains the
yeast Gal4 DNA binding domain fused in-frame to the TAD of
NFAT5 [amino acids 548-1531; kindly provided by Dr. J. Ferraris
(NIH, Bethesda, MD, USA)]. pFR-SEAP (Agilent, Santa Clara,
CA, USA) contains five tandem repeats of the Gal4 binding site
upstream of a minimal promoter and the SEAP ORF. Briefly,
4 × 106 cells were transfected by electroporation with 20µg
pGal4-TonEBP-TAD and 20µg pFR-SEAP (350V, 950µF; 4mm
cuvette) using a Genepulser Xcell apparatus (Bio-Rad), and
subsequently plated into 4–6 wells of a 24-well plate. After 24–
48 h, the cells were treated as indicated and SEAP activity in the
medium was determined as described above.
Statistical Analyses
Data are expressed as means ± S.E.M. The significance of
differences between the means was assessed by Student’s t-test.
P < 0.05 was regarded as significant. All experiments were
performed at least four times and representative results are
shown.
Results
Short-term Exposure to Lithium
First, the effect of a short-term exposure to lithium on NFAT5
activity in renal cells was tested. For this purpose, IMCD-3 or
HEK 293 cells were exposed to 10mM Li2SO4 or 10mMNa2SO4
(as control) for periods of 24 h, under isosmotic (300 mosm/kg
H2O) or hyperosmotic (500 mosm/kg H2O) conditions.
Short-term Exposure to Lithium Increases
Cellular NFAT5 Activity
Cellular NFAT5 activity was measured in HEK 293 cells stably
transfected with a TonE-driven reporter vector. Under isosmotic
conditions a four-fold increase of reporter gene activity in
response to lithium was observed, while under hypertonic
conditions lithium caused a more moderate increase of reporter
gene activity about 25% (Figure 1). These data clearly indicate
that lithium, especially under isosmotic conditions, stimulates
basal cellular NFAT5 activity, but also slightly increases NFAT5
activity under hyperosmotic conditions.
Lithium Increases Expression of the NFAT5
Target Gene HSP70
To test the effect of increased cellular activity of NFAT5 on
expression of NFAT5 target genes, mRNA and protein levels of
HSP70 (as a representative NFAT5 target gene) were evaluated
in IMCD-3 cells (Figures 2A–C). Expression of HSP70 under
isosmotic conditions was enhanced severalfold compared with
control cells. Under hyperosmotic conditions, lithium also
increased expression of HSP70 (although the increase was less
pronounced than under isosmotic conditions), consistent with
the results of lithium-induced enhanced cellular NFAT5 activity.
Cellular NFAT5 Activity Is Increased by Enhanced
Activation of the TAD
To determine the mechanism, by which lithium increases NFAT5
cellular activity, NFAT5 expression and TAD activity were
assessed. NFAT5 expression was assessed in IMCD-3 cells at the
mRNA and protein levels. As shown in Figure 2, hyperosmolality
increased NFAT5 expression, as expected, but lithium had no
significant influence on NFAT5 mRNA or protein levels. The
activity of the C-terminal TAD of NFAT5 was measured in HEK
293 cells, transiently transfected with a binary reporter system.
As shown in Figure 3, lithium increased basal TAD activity
approximately three-fold under isosmotic conditions, compared
with control cells. Also under hyperosmotic conditions, lithium
also significantly increased TAD activity. These results clearly
FIGURE 1 | Short-term exposure to lithium increases cellular NFAT5
activity. HEK 293 cells stably transfected with a reporter construct in which
the SEAP gene is under control of two TonE sites were incubated for 24 h in
isosmotic ( ; 300 mosm/kg H2O) or hyperosmotic (; 500 mosm/kg H2O)
medium and exposed to 10mM Li2SO4 or 10mM Na2SO4 (as control). After
24 h, SEAP activity was measured as described in Methods. Data are means
± SEM for n = 6; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs.
isosmotic control.
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FIGURE 2 | Short-term exposure to lithium increases expression of the NFAT5 target gene HSP70. Confluent IMCD-3 cells were incubated for 24 h in
isosmotic ( ; 300 mosm/kg H2O) or hyperosmotic (; 500 mosm/kg H2O) medium and exposed to 10mM Li2SO4 or 10mM Na2SO4 (as control). (A) Cells were
processed for RNA extraction and the abundance of NFAT5 and HSP70 mRNA transcripts determined by qRT-PCR. Relative mRNA abundance was normalized to
that of β-actin to correct for differences in RNA input. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control. (B) Cells
were processed for immunoblotting. To demonstrate comparable protein loading, the blots were also probed for actin. A representative blot from four independent
experiments is shown. (C) Relative protein abundance of NFAT5 and HSP70 was quantified by densitometric analysis of immunoblots and normalized to that of actin
to correct for differences in protein loading. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control.
FIGURE 3 | Short-term exposure to lithium stimulates the
transactivation domain of NFAT5. HEK 293 cells were electroporated with
pGAL4-TonEBP-TAD and pFR-SEAP as described in Methods. Subsequently,
cells were incubated for 24 h in isosmotic ( ; 300 mosm/kg H2O) or
hyperosmotic (; 500 mosm/kg H2O) medium and exposed to 10mM Li2SO4
or 10mM Na2SO4 (as control). Thereafter, SEAP activity was determined as
described in Methods. Data are means ± SEM for n = 6; *P < 0.05 vs.
hyperosmotic control; #P < 0.05 vs. isosmotic control.
indicate that an enhanced transactivating activity is by far the
most important mechanism for lithium-induced increase of
cellular NFAT5 activity.
Lithium Mediates Inhibitory Phosphorylation of
GSK-3β
Next, we examined the effect of lithium on GSK-3β in IMCD-3
cells. Lithium induced an increase of inhibitory phosphorylation
at Ser9, as shown in Figure 4A. We also tested phosphorylation
status of the kinases AKT and p38, which have been previously
shown to mediate inhibition of GSK-3β in renal cells under
hyperosmotic conditions. We could not detect any substantial
impact of lithium on AKT or p38 activity, under either iso-
or hyper-osmotic conditions. Time-course analysis revealed a
relatively slow lithium-induced inhibitory phosphorylation of
GSK-3β, which reached its maximum after approximately 24 h
(Figure 4B).
Long-term Exposure to Lithium
Additionally, the effect of prolonged exposure to lithium on
NFAT5 activity in renal cells was examined. For this purpose,
IMCD-3 or HEK 293 cells were again exposed to 10mM Li2SO4
or 10mM Na2SO4 (as control) under isosmotic (300 mosm/kg
H2O) or hyperosmotic (500 mosm/kg H2O) conditions, this time
for periods of 48–96 h.
Long-term Exposure to Lithium Decreases
Cellular NFAT5 Activity under Hyperosmotic
Conditions
HEK 293 cells stably transfected with a TonE-driven reporter
vector were incubated for 96 h. Whilst still slightly enhanced
under isosmotic conditions, reporter gene activity in response to
lithium decreased dramatically under hyperosmotic conditions,
compared with control cells (Figure 5A). These data clearly
indicate that prolonged exposure to lithium suppresses cellular
NFAT5 activity under hyperosmotic conditions.
Long-term Exposure to Lithium Decreases
Expression of NFAT5 and HSP70
Next, expression of NFAT5 during long-term lithium exposure
was assessed in IMCD-3 cells. While mRNA levels showed no
significant differences compared to control cells (Figure 5B),
NFAT5 protein abundance declined significantly after 48 h,
especially under hyperosmotic conditions, but also under
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FIGURE 4 | Lithium mediates inhibitory phosphorylation of GSK-3β. (A)
Confluent IMCD-3 cells were incubated for 24 h in isosmotic (300 mosm/kg
H2O) or hyperosmotic (500 mosm/kg H2O) medium and exposed to 10mM
Li2SO4 or 10mM Na2SO4 (as control). Thereafter, cells were processed for
immunoblotting and phosphorylation status of GSK-3β, AKT, and p38 was
determined as described in Methods. A representative blot from four
independent experiments is shown. (B) Time-course of GSK-3β inhibitory
phosphorylation. Confluent IMCD-3 cells were incubated for 0–24 h in
isosmotic medium (300 mosm/kg H2O) in the presence of 10mM Li2SO4.
Thereafter, cells were processed for immunoblotting and phosphorylation
status of GSK-3β was determined as described in Methods. A representative
blot from four independent experiments is shown.
isosmotic conditions; this decline was further enhanced after 96 h
(Figures 5C,D). These results indicate that long-term exposure
to lithium decreases NFAT5 expression and thereby cellular
NFAT5 activity, probably mediated by posttranscriptional
mechanisms.
Expression of the NFAT5 target gene HSP70 under isosmotic
conditions was slightly enhanced compared with control cells,
even after 96 h. Under hyperosmotic conditions, HSP70 protein
levels were significantly decreased after 96 h of exposure to
lithium (Figures 5C,D). These results are consistent with the
observed attenuation of cellular NFAT5 activity.
GSK-3β inhibitory phosphorylation by lithium was still stable
after 96 h (data not shown).
Pharmacological GSK-3β Inhibition Mimics the
Effect of Lithium on NFAT5 Activity
To determine whether lithium-induced downregulation of
NFAT5 is mediated by GSK-3β inhibition, we also examined
the effect of the specific pharmacological GSK-3β inhibitor VIII.
Similar to lithium treatment, under hyperosmotic conditions
both cellular NFAT5 activity (Figure 6A) and expression of
NFAT5 and HSP70 (Figures 6B–D) were decreased significantly
compared with control cells. Under isosmotic conditions, cellular
NFAT5 activity and HSP70 expression in cells treated with
GSK-3β inhibitor VIII were also less than in control cells, in
contrast to lithium treatment. We assume that an even stronger
downregulation of NFAT5 by GSK-3β inhibitor VIII, compared
with lithium, is responsible for this observation. Taken together,
the results suggest that lithium-induced downregulation of
NFAT5 might be mediated by GSK-3β inhibition.
Discussion
The results presented in this study indicate that lithium has two
opposing effects on NFAT5 activity in renal cells: in the first,
“rapid” response to lithium exposure, NFAT5 activity increases.
This increase is probably mediated by inhibition of GSK-3β
and subsequent activation of the c-terminal TAD of NFAT5,
while NFAT5 protein levels are largely unaffected. The group
of Joan Ferraris showed recently that the TAD activity under
isosmotic conditions is suppressed by GSK-3β, and that under
hyperosmotic conditions, inhibitory phosphorylation of GSK-3β
(mediated by AKT, PKA, and PI-3K) interrupts this suppression
(Zhou et al., 2013). The lithium-induced increase of NFAT5
activity was especially pronounced under isosmotic conditions.
Normally, NFAT5 activity under isosmotic conditions is virtually
zero, as illustrated by the minimal expression of the NFAT5 target
gene HSP70. Under these conditions, lithium increases NFAT5
activity and expression of HSP70 severalfold (however, still
less than under hyperosmotic conditions). Under hyperosmotic
conditions, the effect of lithium on NFAT5 activity is more
moderate, probably since GSK-3β is already inhibited under
these conditions, as mentioned above. An additional GSK-
3β inhibition by lithium only slightly enhances TAD activity
(25–50%).
When cells were exposed to lithium for prolonged periods
(up to 96 h), a second, “slow” response was observed: under
hyperosmotic conditions, cellular NFAT5 activity and expression
of NFAT5 target genes decreased, probably due to reduced
NFAT5 protein abundance. The mechanisms, by which lithium-
induced inhibition of GSK-3β mediates NFAT5 downregulation,
are not clear. Normally, NFAT5 protein abundance increases
under hyperosmotic conditions, which, in addition to activation
of TAD, contributes to enhanced cellular NFAT5 activity under
these conditions. Enhanced transcription and increased mRNA
stability have been identified as important mechanisms for
hyperosmolality-induced upregulation of NFAT5 expression (Cai
et al., 2005). Since NFAT5 mRNA levels were largely unaffected
by prolonged exposure to lithium, we assume that translational
or posttranslational mechanisms are probably responsible for
the observed downregulation of NFAT5. Regulation of NFAT5
by such mechanisms has, to date, not been addressed in detail.
In cardiac cells, doxorubicin induces ubiquitin-independent
proteasomal degradation of NFAT5 protein (Ito et al., 2007),
and recent investigations suggest that the long non-coding RNA
“non-coding repressor of NFAT” (NRON) may be involved in
proteasomal NFAT5 degradation (Umekita et al., 2013). We
attempted to establish whether the proteasomal inhibitor MG-
132 influences lithium-induced degradation of NFAT5, but since
exposure of IMCD-3 cells to the combination of hyperosmotic
stress, lithium and MG-132 for periods longer than 24 h caused
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FIGURE 5 | Long-term exposure to lithium decreases cellular NFAT5 activity. HEK 293 cells stably transfected with a reporter construct in which the SEAP
gene is under control of two TonE sites (A) or IMCD-3 cells (B–D) were incubated for 96 h in isosmotic ( ; 300 mosm/kg H2O) or hyperosmotic (; 500 mosm/kg
H2O) medium and exposed to 10mM Li2SO4 or 10mM Na2SO4 (as control). (A) After 96 h, SEAP activity was measured as described in Methods. Data are means ±
SEM for n = 6; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control. (B) IMCD-3 cells were processed for RNA extraction and the abundance of
NFAT5 and HSP70 mRNA transcripts was determined by qRT-PCR. Relative mRNA abundance was normalized to that of β-actin to correct for differences in RNA
input. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control. (C) IMCD-3 cells were processed for immunoblotting.
To demonstrate comparable protein loading, the blots were also probed for actin. A representative blot from four independent experiments is shown. (D) Relative
protein abundance of NFAT5 and HSP70 was quantified by densitometric analysis of immunoblots and normalized to that of actin to correct for differences in protein
loading. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control.
massive cell death, we were not able to obtain significant results
(data not shown).
Of particular interest is the observation that the impact
of prolonged lithium incubation (96 h) on NFAT5 activity
also depends on environmental osmolality. As discussed above,
NFAT5 activity and expression of target gene HSP70 clearly
declines under hyperosmotic conditions. Under isosmotic
conditions, however, NFAT5 activity in lithium treated cells
is higher than in control cells, although NFAT5 protein
abundance slightly decreased.We assume that, in sum, the strong
stimulatory effect of lithium on TAD activity of NFAT5 overrides
the decrease of NFAT5 protein, as also indicated by the increased
expression of HSP70 under these conditions. Transferred to the
situation in the kidney, these results indicate that the effect of
lithium on NFAT5 activity depends not only on the duration
of exposure but also on the kidney region. Cortical collecting
duct cells are not usually exposed to hyperosmotic stress, hence,
NFAT5 activity in this region may be enhanced even during long-
term lithium treatment. In contrast, in collecting duct cells of
the outer and especially the inner medulla, which are regularly
exposed to hyperosmotic conditions, lithium probably decreases
NFAT5 activity and expression of its target genes. Accordingly, a
proteomic analysis demonstrated that expression of the NFAT5
target genes AR and HSP70 is significantly decreased in inner
medullary collecting duct cells in lithium-treated rats (Nielsen
et al., 2008).
The question arises as to whether altered NFAT5 activity
contributes to the well-known renal side effects of lithium
therapy. The molecular mechanisms underlying these side effects
are not completely understood (Behl et al., 2015). Among these
side effects, NDI is the most frequent, affecting up to 40% of
lithium-treated patients. Lithium decreases AQP-2 expression
and trafficking to the luminal membrane of the principal cells
of the collecting duct. Moreover, the urea transporters UT-A
and UT-B, which are necessary for efficient urea circulation in
the kidney and hence for maximal urinary concentration ability,
are downregulated by lithium in a rat model (Klein et al., 2002;
Blount et al., 2010). NFAT5 has been identified as a positive
regulator of AQP-2 (Kasono et al., 2005; Hasler et al., 2006)
and UT-A (Nakayama et al., 2000) expression; additionally,
the NFAT5 target gene AR has been linked to the urinary
concentration mechanism (Aida et al., 2000). Accordingly, in a
mouse model expressing a dominant-negative NFAT5 derivative,
the urinary concentrating ability is decreased (Lam et al., 2004).
In a rat model of sepsis-induced polyuria, inhibitory nitrosylation
of NFAT5 is associated with decreased renal expression of AQP-2,
UT-A1, ClC-K1 and its regulatory subunit barttin, also resulting
in impaired urinary concentration ability (Küper et al., 2012).
These data clearly indicate the importance of NFAT5 for urinary
concentration, and thus it seems plausible that lithium-induced
downregulation of NFAT5, at least in medullary collecting duct
cells, contributes to the development of NDI during lithium
treatment.
Long-term treatment with lithium (>10 years) is also
associated with an enhanced risk of developing CKD (Markowitz
et al., 2000; Presne et al., 2003). The underlying mechanisms
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FIGURE 6 | GSK-3β inhibitor VIII mimics the effect of lithium on cellular NFAT5 activity. HEK 293 cells stably transfected with a reporter construct in which the
SEAP gene is under control of two TonE sites (A) or IMCD-3 cells (B–D) were incubated for 96 h in isosmotic ( ; 300 mosm/kg H2O) or hyperosmotic (; 500
mosm/kg H2O) medium in the presence of 10µM GSK-3β inhibitor VIII or vehicle DMSO (as control). (A) After 96 h, SEAP activity was measured as described in
Methods. Data are means ± SEM for n = 6; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control. (B) IMCD-3 cells were processed for RNA
extraction and the abundance of NFAT5 and HSP70 mRNA transcripts was determined by qRT-PCR. Relative mRNA abundance was normalized to that of β-actin to
correct for differences in RNA input. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control. (C) IMCD-3 cells were
processed for immunoblotting. To demonstrate comparable protein loading, the blots were also probed for actin. A representative blot from four independent
experiments is shown. (D) Relative protein abundance of NFAT5 and HSP70 was quantified by densitometric analysis of immunoblots and normalized to that of actin
to correct for differences in protein loading. Data are means ± SEM for n = 4; *P < 0.05 vs. hyperosmotic control; #P < 0.05 vs. isosmotic control.
are even less well understood than lithium-induced NDI,
thus it is difficult to hypothesize whether downregulation of
NFAT5 contributes to the very slow development of CKD.
Since NFAT5 is an essential regulator for expression of several
important osmoprotective genes it is easily imaginable that
decreased NFAT5 activity might cause renal injury. Indeed,
NFAT5 knockout mice develop severe renal damage (López-
Rodríguez et al., 2004). However, to our knowledge there
are, to date, no reports in the literature that clearly link
decreased expression of one or more NFAT5 target genes
to lithium-induced CKD, thus this subject remains to be
elucidated.
In contrast to these well-known adverse renal side effects
of lithium, recent reports indicate that lithium might be useful
for treatment of acute kidney injury (AKI). In animal models
of ischemia/reperfusion- or toxin-induced AKI, lithium was
protective against renal injury or improved recovery from
AKI (Wang et al., 2009; Talab et al., 2010, 2012; Plotnikov
et al., 2013; Bao et al., 2014). It has been shown before
that upregulation of HSP70 can protect renal cells against
ischemic injury (Aufricht et al., 1998; Yeh et al., 2010;
Wang et al., 2011). Based on the results of the present
study, one may speculate that short exposure to lithium
increases NFAT5 activity in renal cells and thereby stimulates
expression of HSP70 (and perhaps other target genes), which
contribute to the protective effect of lithium against renal
injury.
Can lithium alter cellular NFAT5 activity also in extrarenal
tissues?When lithium is used therapeutically, serum levels of 0,4-
1mM are recommended (National Institute for Health and Care
Excellence, (NICE), 2006). In the present study, significant effects
of lithium on NFAT5 activity in renal cells were only observed
at relative high concentrations (5–10mM Li2SO4, corresponding
to 10–20mM Li+). Due to the concentration mechanism of
the nephron, lithium levels in the collecting duct fluid can
exceed 20mM (Hayslett and Kashgarian, 1979; Birch and Hullin,
1980), indicating that the effects we observed in cell culture
may also be relevant in vivo, at least in the distal nephron
and the collecting duct. Based on our results, it seems unlikely
that the comparatively low serum lithium levels will have a
significant impact onNFAT5 activity in extrarenal cells. However,
accumulation of lithium has also been observed in other tissues
(Thomas et al., 1975; Mendlewicz et al., 1978; Costa et al., 1982;
Kabakov et al., 1998), and thus lithium-mediated altered NFAT5
activity outside the kidney should not be completely ruled out.
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